NDLI: Variability in the Bioavailability of Phenytoin Capsules in Males and Females

Content Provider	Springer Nature Link
Author	Meyer, Marvin C. Straughn, Arthur B. Mhatre, Ramakant M. Shah, Vid P. Chen, Mei Ling Williams, Roger L. Lesko, Lawrence J.
Copyright Year	2001
Abstract	Purpose. To determine inter-lot and intra-subject variability in the bioavailability of the 100 mg extended phenytoin sodium capsules. In addition, to determine the effect of gender and menstrual cycle on phenytoin bioavailability. Methods. Three different lots of extended phenytoin sodium capsules were given to 12 healthy male and 12 healthy female subjects in a crossover fashion. One of the lots was also given a second time to each subject. Plasma phenytoin was determined, using an HPLC assay, in samples collected over a 73-hr period after each dose. Results. The mean Cmax for the four administrations ranged from 1.71-1.79 μg/ml and mean AUC(0-∞) values from ranged 53.0-54.1 μg$_{*}$hr/ml. The elimination half-life was 3 hr shorter, and the AUC(0-∞) adjusted for the mg/kg dose was 30% lower for females. Average bioequivalence was demonstrated between the three lots for both Cmax and AUC(0-∞) based on the BE limit of 80-125%. Further, all confidence intervals of AUC(0-∞) fell within the limit of 90-111%. There were no differences in the confidence limits for Cmax and AUC(0-∞) determined separately for males and females. Also, there was no difference in the mean Cmax or AUC(0-∞) for females when analyzed as a function of the week of their menstrual cycle. Individual bioequivalence was demonstrated between three lots of phenytoin using the constant-scaled method, but not the reference-scaled method. Conclusions. There was very little difference in the bioavailability of the three lots of phenytoin. Females exhibited a lower AUC(0-∞) than males after adjustment of dose for body weight, but their inclusion in the study did not affect the assessment of bioequivalence. When dose was not adjusted for body weight, no difference in AUC(0-∞) was seen between males and females.
Starting Page	394
Ending Page	397
Page Count	4
File Format	PDF
ISSN	07248741
Journal	Pharmaceutical Research
Volume Number	18
Issue Number	3
e-ISSN	1573904X
Language	English
Publisher	Kluwer Academic Publishers-Plenum Publishers
Publisher Date	2001-01-01
Publisher Place	New York
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Pharmacology/Toxicology Pharmacy Biochemistry Medical Law Biomedical Engineering
Content Type	Text
Resource Type	Article
Subject	Organic Chemistry Pharmacology Molecular Medicine Pharmacology (medical) Biotechnology Pharmaceutical Science

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Bioavailability of Phenytoin and Anticonvulsant Activity after Oral Administration of Phenytoin-bis-hydroxyisobutyrate to Rats

Bioavailability and Bioequivalence: Focus on Physiological Factors and Variability

Bioavailability and Bioequivalence: An FDA Regulatory Overview

Assessment of Lumiracoxib Bioavailability from Targeted Sites in the Human Intestine Using Remotely Activated Capsules and Gamma Scintigraphy

On the Variability of Dissolution Data

Using Partial Area for Evaluation of Bioavailability and Bioequivalence

Polyethylene Glycol 400 Enhances the Bioavailability of a BCS Class III Drug (Ranitidine) in Male Subjects but Not Females

Rebuttal Letter

Variability in the Bioavailability of Phenytoin Capsules in Males and Females

Similar Documents

Bioavailability of Phenytoin and Anticonvulsant Activity after Oral Administration of Phenytoin-bis-hydroxyisobutyrate to Rats

Bioavailability and Bioequivalence: Focus on Physiological Factors and Variability

Bioavailability and Bioequivalence: An FDA Regulatory Overview

Assessment of Lumiracoxib Bioavailability from Targeted Sites in the Human Intestine Using Remotely Activated Capsules and Gamma Scintigraphy

On the Variability of Dissolution Data

Using Partial Area for Evaluation of Bioavailability and Bioequivalence

Polyethylene Glycol 400 Enhances the Bioavailability of a BCS Class III Drug (Ranitidine) in Male Subjects but Not Females

Rebuttal Letter

Variability in the Bioavailability of Phenytoin Capsules in Males and Females